Pfizer Inc. (NYSE:PFE - Get Free Report) rose 0% during trading on Tuesday . The stock traded as high as $25.74 and last traded at $25.54. Approximately 13,407,105 shares changed hands during trading, a decline of 64% from the average daily volume of 37,195,734 shares. The stock had previously closed at $25.53.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on PFE shares. Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Guggenheim reissued a "buy" rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Wolfe Research started coverage on Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective for the company. Finally, Bank of America reaffirmed a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $31.92.
Read Our Latest Research Report on Pfizer
Pfizer Price Performance
The stock has a market cap of $149.14 billion, a price-to-earnings ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The stock has a fifty day simple moving average of $26.28 and a 200-day simple moving average of $27.44. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the company earned $0.10 EPS. The company's quarterly revenue was up 24.7% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio (DPR) is currently 121.99%.
Insiders Place Their Bets
In related news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.06% of the company's stock.
Hedge Funds Weigh In On Pfizer
Several hedge funds and other institutional investors have recently modified their holdings of PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the 4th quarter valued at $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the 4th quarter valued at $27,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at $28,000. Finally, Gladius Capital Management LP increased its stake in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 38,015 shares during the period. Institutional investors own 68.36% of the company's stock.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
